A research update in Richter's transformation from ASH 2023

A research update in Richter's transformation from ASH 2023Подробнее

CAR-T Therapy for Richter Transformation - Dr. Adam Kittai ASH 2023Подробнее

Incidence of Richter’s Transformation in the Targeted Therapy Era - Dr. Paul Hampel ASH 2023Подробнее

Promising agents emerging for Richter’s transformationПодробнее

Biology and Genetics of Richter’s TransformationПодробнее

Venetoclax, Obinutuzumab, and Atezolizumab for Richter's Transformation - Dr. Nitin Jain ASH 2021Подробнее

Richter's Transformation & CAR T Therapy in #CLL | Dr. Adam Kittai, MD | ASH 2023Подробнее

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformationПодробнее

Pirtobrutinib for Richter's Transformation - Dr. William Wierda ASH 2023Подробнее

Triple Combination Therapy for Richter’s Transformation - Dr. Tamar Tadmor ASH 2023Подробнее

Risk-factors for Richter’s transformationПодробнее

Tislelizumab Plus Zanubrutinib for Richter’s Transformation - Dr. Barbara Eichhorst ASH 2023Подробнее

Var-cel shows promise for the treatment of CLL and Richter's transformationПодробнее

Novel treatment regimens under investigation for Richter's transformationПодробнее

The current SoC in Richter’s transformation and the potential role of CAR T-cell therapyПодробнее

Pirtobrutinib for Richter’s Transformation - Dr. Nirav Shah ASH 2022Подробнее

Outcomes of patients with Richter's transformation without prior chemoimmunotherapy for CLL/SLLПодробнее

Designing Research Trials for Richter’s Transformation - Dr. Adam KittaiПодробнее

Richter's Transformation after CAR-T Therapy in CLL (Chronic Lymphocytic Leukemia) - ASH 2021Подробнее